Vaccines under development are designed to intervene with immune components of the TME, secreted proteins (mucins), as well as proteins expressed by cancer cells which directly or indirectly facilitate PDAC invasiveness (KRAS and kinesins). This evidence concerns the gene KRAS and cancer.